Interferon- therapy prolongs survival in rhesus macaque models of ebola and marburg hemorrhagic fever

Journal of Infectious Diseases

Volumn 208, Issue 2, 2013, Pages 310-318

  Smith, Lauren M ^a,e   Hensley, Lisa E ^b,f   Geisbert, Thomas W ^b,g   Johnson, Joshua ^b   Stossel, Andrea ^b   Honko, Anna ^b   Yen, Judy Y ^b   Geisbert, Joan ^b,g   Paragas, Jason ^b,h   Fritz, Elizabeth ^b,g   Olinger, Gene ^b   Young, Howard A ^c   Rubins, Kathleen H ^a,i   Karp, Christopher L ^d,j  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g University of Texas Medical Branch School of Medicine   (United States)

^h DEFENSE THREAT REDUCTION AGENCY   (United States)

ⁱ NASA JOHNSON SPACE CENTER   (United States)

^j BILL AND MELINDA GATES FOUNDATION   (United States)

more..

Author keywords

Filovirus; IFN Ebola virus; Marburg virus; type I interferon

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BETA1A INTERFERON; INTERFERON RECEPTOR; RECOMBINANT PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; FEMALE; FEVER; FUNCTIONAL GENOMICS; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOREGULATION; LYMPHOCYTE; MALE; MARBURG HEMORRHAGIC FEVER; NONHUMAN; PRIORITY JOURNAL; RASH; RECEPTOR BLOCKING; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; ANIMAL; DRUG EFFECT; EBOLA VIRUS; FILOVIRUS; HUMAN; IFN-Β; MARBURG VIRUS; RHESUS MONKEY; TYPE I INTERFERON; VIROLOGY;

EBOLA VIRUS; FILOVIRUS; IFN-Β; MARBURG VIRUS; TYPE I INTERFERON;

ANIMALS; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; INTERFERON-BETA; MACACA MULATTA; MALE; MARBURG VIRUS DISEASE; MARBURGVIRUS; RECOMBINANT PROTEINS;

EID: 84878907971     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis921     Document Type: Article

References (50)

1. Sanchez A, Kahn AS, ZS R, Nabel GL, Ksiazek TG, Peters CJ. Filoviridae. In: Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott, Williams & Wilkins, 2001:1279-304
2. Geisbert TW, Hensley LE. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 2004; 6:1-24
3. Bausch DG, Nichol ST, Muyembe-Tamfum JJ, et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med 2006; 355:909-19 (Pubitemid 44315983)
4. Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, et al. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis 2007; 196(suppl 2):S372-81 (Pubitemid 351417284)
5. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 2008; 82:5664-8 (Pubitemid 351705275)
6. Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010; 375:1896-905
7. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188:1618-29 (Pubitemid 38010671)
8. Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003; 362:1953-8 (Pubitemid 37548417)
9. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000; 80:171-86 (Pubitemid 30120970)
10. Baize S, Leroy EM, Georges-Courbot MC, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999; 5:423-6 (Pubitemid 29180581)
11. Baize S, Leroy EM, Mavoungou E, Fisher-Hoch SP. Apoptosis in fatal Ebola infection. Does the virus toll the bell for immune system? Apoptosis 2000; 5:5-7 (Pubitemid 30146383)
12. Baskerville A, Satti A, Murphy FA, Simpson DI. Congo-Crimean haemorrhagic fever in Dubai: histopathological studies. J Clin Pathol 1981; 34:871-4 (Pubitemid 11060148)
13. Monath TP, Brinker KR, Chandler FW, Kemp GE, Cropp CB. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am J Trop Med Hyg 1981; 30:431-43 (Pubitemid 11117231)
14. Walker DH, McCormick JB, Johnson KM, et al. Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol 1982; 107:349-56 (Pubitemid 12084836)
15. Bray M, Geisbert TW. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 2005; 37:1560-6 (Pubitemid 40719635)
16. Basler CF, Amarasinghe GK. Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res 2009; 29:511-20
17. Halfmann P, Neumann G, Kawaoka Y. The Ebolavirus VP24 protein blocks phosphorylation of p38 mitogen-activated protein kinase. J Infect Dis 2011; 204(suppl 3):S953-6
18. Gupta M, Mahanty S, Ahmed R, Rollin PE. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with Ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-ICinduced IFN-alpha in vitro. Virology 2001; 284:20-5 (Pubitemid 32476692)
19. Villinger F, Rollin PE, Brar SS, et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 1999; 179(suppl 1):S188-91 (Pubitemid 29091401)
20. Hensley LE, Young HA, Jahrling PB, Geisbert TW. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 2002; 80:169-79 (Pubitemid 34136004)
21. Masuyama T, Matsuo M, Ichimaru T, Ishii K, Tsuchiya K, Hamasaki Y. Possible contribution of interferon-alpha to febrile seizures in influenza. Pediatr Neurol 2002; 27:289-92 (Pubitemid 35341701)
22. Ronnblom LE, Perers A, Vallin HS, et al. Detection of serum interferon- alpha by dissociation-enhanced lanthanide fluoroimmunoassay. Studies of patients with acute viral and bacterial infections. Apmis 1997; 105:531-6
23. Shiozawa S, Yoshikawa N, Iijima K, Negishi K. A sensitive radioimmunoassay for circulating alpha-interferon in the plasma of healthy children and patients with measles virus infection. Clin Exp Immunol 1988; 73:366-9
24. von Sydow M, Sonnerborg A, Gaines H, Strannegard O. Interferonalpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses 1991; 7:375-80
25. Stylianou E, Aukrust P, Bendtzen K, Muller F, Froland SS. Interferons and interferon (IFN)-inducible protein 10 during highly active antiretroviral therapy (HAART) - possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol 2000; 119:479-85 (Pubitemid 30146344)
26. Full prescribing information for INFERGEN® (interferon alfacon-1). Cranberry Township, PA: Three Rivers Pharmaceuticals:1-10 2012.
27. Li L, Sherry B. IFN-alpha expression and antiviral effects are subtype and cell type specific in the cardiac response to viral infection. Virology 2010; 396:59-68
28. van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006; 25:361-72 (Pubitemid 44354225)
29. Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis 1999; 179(suppl 1):S224-34 (Pubitemid 29091406)
30. Jahrling PB, Geisbert J, Swearengen JR, et al. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 1996; 11:135-40 (Pubitemid 126446186)
31. Smith DH, Johnson BK, Isaacson M, et al. Marburg-virus disease in Kenya. Lancet 1982; 1:816-20 (Pubitemid 12133655)
32. Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol 2009; 83:7296-304
33. Geisbert TW, Hensley LE, Larsen T, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163:2347-70 (Pubitemid 37466478)
34. Council NR. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996
35. Daddario-DiCaprio KM, Geisbert TW, Stroher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 2006; 367:1399-404
36. Geisbert TW, Hensley LE, Geisbert JB, et al. Postexposure treatment of Marburg virus infection. Emerg Infect Dis 2010; 16:1119-22
37. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52
38. Dillman JF 3rd, Phillips CS. Comparison of non-human primate and human whole blood tissue gene expression profiles. Toxicol Sci 2005; 87:306-14 (Pubitemid 41222683)
39. Chismar JD, Mondala T, Fox HS, et al. Analysis of result variability from high-density oligonucleotide arrays comparing same-species and cross-species hybridizations. Biotechniques 2002; 33:516-8, 520, 522 passim
40. Rubins KH, Hensley LE, Wahl-Jensen V, et al. The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol 2007; 8:R174
41. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 2009; 10:48
42. Ochs MF, Peterson AJ, Kossenkov A, Bidaut G. Incorporation of gene ontology annotations to enhance microarray data analysis. Methods Mol Biol 2007; 377:243-54 (Pubitemid 350183376)
43. Hensley LE, Stevens EL, Yan SB, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007; 196(suppl 2):S390-9 (Pubitemid 351417286)
44. Jahrling PB. Filoviruses and Arenaviruses. In: Murray PR, Baron EJ, Pfaller M, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. Washington, DC: ASM Press, 1999:1125-36
45. Larsen T, Stevens EL, Davis KJ, et al. Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J Infect Dis 2007; 196(suppl 2):S323-8 (Pubitemid 351417278)
46. Baize S, Leroy EM, Georges AJ, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002; 128:163-8 (Pubitemid 34451194)
47. Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003; 163:2371-82 (Pubitemid 37474154)
48. Jungo F, Dayer JM, Modoux C, Hyka N, Burger D. IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact. Cytokine 2001; 14:272-82 (Pubitemid 32692605)
49. Khabar KS, Young HA. Post-transcriptional control of the interferon system. Biochimie 2007; 89:761-9 (Pubitemid 47001636)
50. Raymond J, Bradfute S, Bray M. Filovirus infection of STAT-1 knockout mice. J Infect Dis 2011; 204(suppl 3):S986-90